Drug-eluting balloons with provisional bail-out or adjunctive stenting in de novo coronary artery lesions—a systematic review and meta-analysis

Patel, Smit; Svermova, Tatiana; Burke-Gaffney, Anne; Bogle, Richard

doi:10.21037/cdt.2017.10.09

Cited by 5 publications

(3 citation statements)

References 43 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of DCBs is associated with positive vessel remodeling, vascular healing inducing late lumen enlargement, and plaque reduction and stabilization . A disadvantage to using DCB is the possibility of suboptimal results in some patients secondary to persistent residual stenosis and dissections, necessitating bailout stenting …”

Section: Discussionsupporting

confidence: 89%

“…15,41 A disadvantage to using DCB is the possibility of suboptimal results in some patients secondary to persistent residual stenosis and dissections, necessitating bailout stenting. 42 Our results showed similar angiographic and long-term clinical outcomes with DCB versus DES in treating small-vessel de novo CAD, and better outcomes when compared with BA alone. The outcomes remained comparable when DCB was compared only to newergeneration DES.…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

Outcomes with drug‐coated balloons in small‐vessel coronary artery disease

Megaly

Rofael

Saad

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

Background Percutaneous coronary intervention (PCI) of small‐vessel coronary artery disease (SVD) is associated with increased risk of restenosis. The use of drug‐coated balloons (DCBs) in SVD has received limited study. Objectives To assess the outcomes of DCB in the treatment of SVD compared with the standard of care. Methods We performed a meta‐analysis of all studies published between January 2000 and September 2018 reporting the outcomes of DCB versus other modalities in the treatment of de novo SVD. Results Seven studies with 1,824 patients (1,938 lesions) were included (four randomized controlled trials and three observational studies). During a mean follow‐up of 14.5 ± 10 months, DCBs were associated with a similar risk of target lesion revascularization (TLR) (OR: 0.99, 95% CI: 0.54, 1.84, P = 97) and major adverse cardiovascular events (MACE) (OR: 0.86, 95% CI: 0.51, 1.45, P = 0.57) compared with drug‐eluting stents (DES). During a mean follow‐up of 7 ± 1.5 months, DCBs were associated with a significantly lower risk of TLR (OR: 0.19, 95% CI 0.04–0.88, P = 0.03) and binary restenosis (OR: 0.17, 95% CI 0.08–0.37, P = <0.00001) compared with noncoated balloon angioplasty. Conclusion The use of DCBs in SVD is associated with comparable outcomes when compared with DES and favorable outcomes when compared with balloon angioplasty.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 66%

Outcomes with drug‐coated balloons in small‐vessel coronary artery disease

Megaly

Rofael

Saad

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…In the past decade, a tremendous effort has been made to develop alternative strategies to overcome the limitations of the increased metal length implanted in the coronary arteries. One of the most studied alternatives are drug-coated balloons (DCB), which have the ability to homogeneously transfer drugs to the vessel wall without the need for prosthesis implantation 5 . The encouraging results in terms of safety and efficacy of DCB reported for in-stent restenosis (ISR) and small vessel disease (SVD) have led to continuous work in refining their still unclear role in native large coronary arteries.…”

Section: Introductionmentioning

confidence: 99%

A 2024 scientific update on the clinical performance of drug-coated balloons

Lazar,

Onea,

Olinic

et al. 2024

AsiaIntervention

View full text Add to dashboard Cite

Continuous advances in the field of interventional cardiology have led to the development of drug-coated balloons (DCB). These represent a promising device for overcoming the well-known limitations of traditional metallic stents, which are associated with a persistent yearly increased risk of adverse events. This technology has the ability to homogeneously transfer the drug into the vessel wall in the absence of a permanent prosthesis implanted in the coronary vessel.Robust data support the use of DCB for the treatment of in-stent restenosis, but there is also currently growing evidence from long-term follow-up of large randomised clinical trials regarding the use of these devices in other scenarios, such as de novo small and large vessel disease, complex bifurcations, and diffuse coronary disease. Other critical clinical settings such as diabetes mellitus, high bleeding risk patients and acute coronary syndromes could be approached in the upcoming future by using DCB, alone or as part of a blended strategy in combination with drug-eluting stents.There have been important scientific and technical advances in the DCB field in recent years. The purpose of this paper is to review the most current data regarding the use of DCB, including the mid-and long-term follow-up reports on the safety and efficacy of this novel strategy in different clinical and angiographic scenarios.

show abstract

Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease

Megaly

Saad

Brilakis

2019

US Cardiology Review

View full text Add to dashboard Cite

Percutaneous coronary intervention of small-vessel coronary artery disease (SVD) remains challenging due to difficulties with device delivery and high restenosis rate, even with the use of newer-generation drug-eluting stents. Drug-coated balloons represent an attractive emerging percutaneous coronary intervention option in patients with SVD. Potential advantages of drug-coated balloons in SVD include enhanced deliverability because of their small profile, avoidance of foreign-body implantation, and shorter duration of dual antiplatelet therapy.

show abstract

Drug-eluting balloons with provisional bail-out or adjunctive stenting in de novo coronary artery lesions—a systematic review and meta-analysis

Cited by 5 publications

References 43 publications

Outcomes with drug‐coated balloons in small‐vessel coronary artery disease

Outcomes with drug‐coated balloons in small‐vessel coronary artery disease

A 2024 scientific update on the clinical performance of drug-coated balloons

Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease

Contact Info

Product

Resources

About